Edition:
United States

Intrexon Corp (XON.N)

XON.N on New York Stock Exchange

15.73USD
4:02pm EDT
Change (% chg)

$-1.27 (-7.47%)
Prev Close
$17.00
Open
$16.90
Day's High
$17.00
Day's Low
$15.65
Volume
271,297
Avg. Vol
281,870
52-wk High
$25.85
52-wk Low
$10.26

Latest Key Developments (Source: Significant Developments)

Intrexon Q1 Revenue Fell 18 Percent To $43.8 Million
Thursday, 10 May 2018 04:05pm EDT 

May 10 (Reuters) - Intrexon Corp ::INTREXON ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS.Q1 REVENUE FELL 18 PERCENT TO $43.8 MILLION.Q1 REVENUE VIEW $60.4 MILLION -- THOMSON REUTERS I/B/E/S.QTRLY NET LOSS OF $0.33 PER BASIC SHARE.  Full Article

Intrexon Corp Q4 Loss Per Share $‍0.23​
Thursday, 1 Mar 2018 04:05pm EST 

March 1 (Reuters) - Intrexon Corp ::INTREXON ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS.Q4 REVENUE ROSE 67 PERCENT TO $77 MILLION.QTRLY LOSS PER SHARE $‍0.23​.  Full Article

Intrexon Announces Proposed Public Offering Of Common Stock
Tuesday, 16 Jan 2018 04:15pm EST 

Jan 16 (Reuters) - Intrexon Corp ::INTREXON ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.  Full Article

Intrexon posts Q3 qtrly ‍net loss per share $0.33​
Thursday, 9 Nov 2017 04:05pm EST 

Nov 9 (Reuters) - Intrexon Corp :Intrexon announces third quarter 2017 financial results.Q3 revenue $46 million versus I/B/E/S view $55.1 million.Intrexon corp - qtrly ‍net loss per share $0.33​.Q3 earnings per share view $-0.23 -- Thomson Reuters I/B/E/S.  Full Article

Agilis Biotherapeutics announces orphan product designation approval in Europe for the treatment of friedreich ataxia
Tuesday, 31 Oct 2017 07:30am EDT 

Oct 31 (Reuters) - Agilis Biotherapeutics :Agilis Biotherapeutics announces orphan product designation approval in Europe for the treatment of friedreich ataxia.‍agilis Biotherapeutics says EC granted orphan medicinal product designation in EU to company's gene therapy product candidate, AGIL-FA​.‍agilis Biotherapeutics says company has completed a pre-IND meeting with FDA and is on track to open an IND in 2018​.  Full Article

Intrexon and Arch Pharmalabs collaborate on fermentative production of an API to replace existing process sourced from animals
Monday, 23 Oct 2017 08:00am EDT 

Oct 23 (Reuters) - Arch Pharmalabs Ltd :Intrexon and Arch Pharmalabs collaborate on fermentative production of an API to replace existing process sourced from animals.Intrexon Corp - ‍Arch Pharmalabs will have exclusive access to co's technologies for fermentation-based production of specific API.Intrexon - Will receive technology access fee, milestone payments, as well as a 40% royalty based on gross profit of commercialized products.  Full Article

Intrexon enters into $100 mln preferred stock equity facility
Monday, 16 Oct 2017 04:13pm EDT 

Oct 16 (Reuters) - Intrexon Corp :Intrexon Corporation enters into $100 million preferred stock equity facility.Intrexon Corp - ‍under facility, Intrexon may, at its discretion, sell to investor up to $100 million of newly issued series a redeemable preferred stock​.  Full Article

OXITEC SAYS FRIENDLY AEDES REGULATORY JURISDICTION TRANSFERRED
Wednesday, 4 Oct 2017 01:00pm EDT 

Oct 4 (Reuters) - Oxitec::SAYS AFTER GUIDANCE ISSUED BY U.S. FDA-CVM, REGULATORY JURISDICTION FOR OXITEC'S FRIENDLY AEDES MOSQUITO WILL NOW MOVE UNDER EPA AS PESTICIDE PRODUCT ​.  Full Article

Intrexon files for potential mixed shelf size not disclosed - SEC filing‍​
Friday, 1 Sep 2017 05:35pm EDT 

Sept 1 (Reuters) - Intrexon Corp :Files for potential mixed shelf; size not disclosed - SEC filing‍​.  Full Article

Intrexon Q2 loss per share $ 0.16
Wednesday, 9 Aug 2017 04:05pm EDT 

Aug 9 (Reuters) - Intrexon Corp :Intrexon announces second quarter and first half 2017 financial results.Q2 revenue $54.4 million versus I/B/E/S view $57.2 million.Qtrly loss per share $ 0.16.  Full Article

BRIEF-Intrexon Q1 Revenue Fell 18 Percent To $43.8 Million

* QTRLY NET LOSS OF $0.33 PER BASIC SHARE Source text for Eikon: Further company coverage: